Identification and Management of Tardive Dyskinesia 2022

This presentation on the identification and management of tardive dyskinesia 2022 reviews the relative prevalence of TD in patients with schizophrenia, mood spectrum disorders, and anxiety disorders; and the effective use of VMAT2 inhibitors without discontinuing other essential psychiatric treatments such as antipsychotics and antidepressants.
Christoph U. Correll, MD
Robert O. Cotes, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.89 MB
Released: May 11, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by an educational grant from:
Neurocrine Biosciences, Inc.

Related Content

Slides from a presentation that educates clinicians on antipsychotic treatment of schizophrenia.

Christoph U. Correll, MD Robert O. Cotes, MD Released: May 11, 2022

Slides from a presentation that educates clinicians on managing major depression.

Manish Jha, MD Greg W. Mattingly, MD Released: May 11, 2022

Slides from a presentation that educates clinicians on managing bipolar depression and mixed presentations

Charles DeBattista, MD Roger McIntyre, MD, FRCPC Released: May 9, 2022

Slides from a presentation that educates clinicians on recent updates in ADHD treatment

Greg W. Mattingly, MD Joel L. Young, MD Released: May 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings